My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Intra-Cellular Therapies Inc. - Common Stock (NQ:ITCI)

131.87 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Intra-Cellular Therapies Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Analyst Ratings for Intra-Cellular Therapies ↗

March 02, 2023

Via Benzinga

Earnings Scheduled For March 1, 2023 ↗

March 01, 2023

Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.

Via Benzinga

Earnings Outlook For Intra-Cellular Therapies ↗

February 28, 2023

Via Benzinga

Looking Into Intra-Cellular Therapies's Return On Capital Employed ↗

November 23, 2022

Via Benzinga

Recap: Intra-Cellular Therapies Q3 Earnings ↗

November 03, 2022

Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Intra-Cellular Therapies's Earnings: A Preview ↗

November 02, 2022

Intra-Cellular Therapies (NASDAQ:ITCI) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Looking Into Intra-Cellular Therapies's Return On Capital Employed ↗

September 02, 2022

Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $55.58 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 20.08%, resulting in a loss of $86.60...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022 ↗

August 22, 2022

Upgrades

Via Benzinga

Where Intra-Cellular Therapies Stands With Analysts ↗

August 11, 2022

Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings:

Via Benzinga

Robust Uptake Of Antipsychotic Drug Boosts Intra-Cellular's Q1 Earnings ↗

May 10, 2022

Via Benzinga

Illumina, Poshmark, Olo And Some Other Big Losers From Friday ↗

August 15, 2022

U.S. stocks closed higher on Friday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Intra-Cellular Therapies: Q2 Earnings Insights ↗

August 09, 2022

Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Analyst Ratings for Intra-Cellular Therapies ↗

July 07, 2022

Over the past 3 months, 4 analysts have published their opinion on Intra-Cellular Therapies (NASDAQ:ITCI) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022 ↗

July 07, 2022

Upgrades

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 ↗

June 14, 2022

Upgrades

Via Benzinga

Looking Into Intra-Cellular Therapies's Return On Capital Employed ↗

June 09, 2022

According to Benzinga Pro data, during Q1, Intra-Cellular Therapies (NASDAQ:ITCI) posted sales of $35.00 million. Earnings were up 15.88%, but Intra-Cellular Therapies still reported an overall loss of...

Via Benzinga

Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating ↗

May 11, 2022

Intra-Cellular Therapies stock cleared a key performance benchmark, with its Relative Strength (RS) Rating, rising to 97.

Via Investor's Business Daily

103 Biggest Movers From Yesterday ↗

May 11, 2022

Gainers

Via Benzinga

77 Stocks Moving In Tuesday's Mid-Day Session ↗

May 10, 2022

Gainers

Via Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap: Intra-Cellular Therapies Q1 Earnings ↗

May 10, 2022

Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 22, 2022 ↗

April 22, 2022

Upgrades

Via Benzinga

What 4 Analyst Ratings Have To Say About Intra-Cellular Therapies ↗

April 21, 2022

Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter:

Via Benzinga

Stocks That Hit 52-Week Highs On Thursday ↗

April 07, 2022

On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...

Via Benzinga

Intra-Cellular Therapies's Return On Capital Employed Insights ↗

March 04, 2022

Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $25.67 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 11.48%, resulting...

Via Benzinga

What 6 Analyst Ratings Have To Say About Intra-Cellular Therapies ↗

March 02, 2022

Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Intra-Cellular Therapies: Q4 Earnings Insights ↗

March 01, 2022

Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement...

Via Benzinga

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗

March 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.